Risk–benefit stratification for immune checkpoint inhibitor therapy in head and neck cancer based on immune-related adverse events and treatment discontinuation using routine clinical indicators beyond PD-L1 expression
Open Access
- 19 March 2026
- journal article
- Published by Elsevier in Oral Oncology
- Vol. 176, 107938
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCCJAMA Network Open, 2024
- Low skeletal muscle mass predicts melanoma-specific survival in melanoma patients treated with adjuvant immune checkpoint blockadeJournal of Cancer Research and Clinical Oncology, 2024
- Association between baseline lactate dehydrogenase and immune-related adverse events among patients with melanoma varies by tumor stage at immune checkpoint inhibitor initiationJournal of the American Academy of Dermatology, 2023
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With CancerJAMA Oncology, 2021
- Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancerAuris Nasus Larynx, 2021
- Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysisCancer Treatment Reviews, 2021
- Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2020
- Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphomaJAAD Case Reports, 2018
- Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic reviewEuropean Journal of Cancer, 2016
- Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Leptin Axis Causes Cancer Remission and InhibitionCell, 2010